Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680420 | 0.71 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL7766761 | 0.68 | CYP3A4 (0.40) | CYP2D6CYP1A2CYP3A4PRMT1CTSL | |
| SCHEMBL9800583 | 0.67 | CYP2D6 (0.59) | CYP2D6CYP1A2CYP3A4PRMT1CTSL | |
| SCHEMBL7561243 | 0.66 | CYP1A2 (0.57) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL12879664 | 0.66 | CYP2D6 (0.68) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| Bromide SCHEMBL20854775 | 0.66 | CYP1A2 (0.57) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL1654642 | 0.64 | CYP1A2 (1.00) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL11188983 | 0.64 | CYP2D6 (0.66) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL10920937 | 0.64 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL10136448 | 0.64 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| EP-1521752-B1 | MACROCYCLES FOR THE TREATMENT OF CANCER | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2009-02-25 | — | — | EP | disclosed |
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | MORPHONCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | WOLFGANG RICHTER (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1567524-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | Richter, Wolfgang (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1521752-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | Gesellschaft fur Biotechnologische Forschung mbH (gbf) (DE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004048372-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | MORPHOCHEM AG KOMB CHEMIE (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004007492-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | GESELLSCHAFT FUER BIOTECHNOLGISCHE FORSCHUNG MBH (GBF) (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128966-A1 | Thia-epothilone derivatives for the treatment of cancer | TTPA, THPO, TERT | CYP2D6 654/4885CYP1A2 312/4885CYP3A4 749/4885 |
| US-20060004065-A1 | Novel macrocycles for the treatment of cancer | CCNI, CCNB1, CCNC | CYP2D6 1269/4885CYP1A2 948/4885CYP3A4 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.